Cue Biopharma to Participate in Fireside Chat at the Cantor Global Healthcare Conference

Core Insights - Cue Biopharma, Inc. is participating in the Cantor Global Healthcare Conference from September 3-5, 2025, to discuss advancements in its Immuno-STAT platform and the development of its lead autoimmune asset, CUE-401 [1][2]. Company Overview - Cue Biopharma is a clinical-stage biopharmaceutical company focused on developing a novel class of injectable biologics that selectively engage and modulate disease-specific T cells within the patient's body [4]. - The company's proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells), aims to utilize the body's intrinsic immune system for therapeutic purposes while minimizing adverse effects associated with broad systemic immune modulation [4]. Presentation Details - The fireside chat at the Cantor Global Healthcare Conference is scheduled for September 5, 2025, from 8:00 a.m. to 8:30 a.m. EDT, presented by CEO Daniel Passeri [3]. - A live and archived webcast of the presentation will be available on the company's website for 30 days [3].